SI-BONE, Inc. (SIBN)
| Market Cap | 546.85M |
| Revenue (ttm) | 200.93M |
| Net Income (ttm) | -18.90M |
| Shares Out | 44.24M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 532,077 |
| Open | 13.11 |
| Previous Close | 13.15 |
| Day's Range | 12.30 - 13.47 |
| 52-Week Range | 12.15 - 21.89 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 23.88 (+93.2%) |
| Earnings Date | May 11, 2026 |
About SIBN
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the impla... [Read more]
Financial Performance
In 2025, SI-BONE's revenue was $200.93 million, an increase of 20.19% compared to the previous year's $167.18 million. Losses were -$18.90 million, -38.85% less than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for SIBN stock is "Strong Buy." The 12-month stock price target is $23.88, which is an increase of 93.20% from the latest price.
News
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bo...
SI-BONE Transcript: TD Cowen 46th Annual Health Care Conference
The company is expanding its portfolio and market reach through physician-driven innovation, strategic partnerships like Smith+Nephew, and a robust pipeline targeting unmet needs in spine and trauma. Strong growth, margin focus, and regular new product launches are expected to drive performance through 2028.
SI-BONE Earnings Call Transcript: Q4 2025
Record 2025 revenue and first full year of positive adjusted EBITDA highlight strong execution, with robust physician adoption, new product launches, and favorable reimbursement driving growth. 2026 guidance anticipates 14–16% revenue growth, margin stability, and continued innovation.
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026
SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%
SI-BONE Transcript: Piper Sandler 37th Annual Healthcare Conference
Strong Q3 results featured 21% revenue growth, expanding physician adoption, and robust gross margins. Product innovation and reimbursement tailwinds support continued growth, with new devices targeting large unmet needs and further market penetration expected.
SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025
SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be parti...
SI-BONE Earnings Call Transcript: Q3 2025
Q3 2025 saw 21% revenue growth, positive adjusted EBITDA, and record physician additions. Guidance for 2025 was raised, with strong U.S. and international momentum, expanding product portfolio, and improving cash flow positioning the company for continued growth and profitability.
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance
Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter
SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025
SANTA CLARA, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial resul...
SI-BONE Transcript: Barclays 23rd Annual Global Financial Services Conference
The business has evolved into a diversified, high-growth platform with strong innovation in sacropelvic solutions, robust financial performance, and expanding market penetration. Key growth drivers include new product launches, favorable reimbursement changes, and a stable, experienced leadership team.
SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025
SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be parti...
SI-BONE Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Strong Q2 results and raised guidance reflect broad-based growth, margin expansion, and operational leverage. Favorable reimbursement, a robust product pipeline, and significant market opportunity position the business for sustained top-line growth and profitability into 2026.
SI-BONE Earnings Call Transcript: Q2 2025
Q2 2025 saw 22% revenue growth, record physician adoption, and positive adjusted EBITDA, with strong U.S. performance and early international momentum. Updated guidance reflects continued growth, margin expansion, and investments in innovation and capacity.
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance
Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven
SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be parti...
SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025
SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial resul...
SI-BONE Transcript: 2025 Truist Securities MedTech Conference
The company has expanded its product portfolio and market reach, driving record surgeon adoption and accelerating revenue growth. Strategic investments in R&D and sales force expansion support continued innovation and deeper market penetration, with strong financial performance and operating leverage.
SI-BONE Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
Strong revenue and physician growth are driven by innovative, asset-light products addressing unmet needs in the sacral pelvic space. Industry-leading margins, expanding product portfolio, and robust physician education support sustainable profitability and long-term growth.
SI-BONE to Truist Securities MedTech Conference on June 17, 2025
SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be parti...
SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be parti...
SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025
SANTA CLARA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be partic...
SI-BONE Transcript: BofA Securities 2025 Healthcare Conference
Strong Q1 results were driven by broad-based growth, new product adoption, and record physician engagement. Guidance remains prudent, with continued investment in innovation and commercial expansion. Interventional and core SI joint markets are key growth drivers, with new products set for 2026.